Patient Surveillance After Cancer Treatment: Current Clinical Oncology
Editat de Frank E. Johnson, Yoshihiko Maehara, George P. Browman, Julie A. Margenthaler, Riccardo A. Audisio, John F. Thompson, David Y. Johnson, Craig C. Earle, Katherine S. Virgoen Limba Engleză Hardback – 8 mar 2013
The audience includes all oncologists, cancer researchers, medical economists and policy makers in government and insurance companies, and finally, interested patients.
This book is part of the Current Clinical Oncology series, which provides cutting-edge knowledge of cancer diagnosis, management, and treatment. World renowned experts share their insights in all the major fields of clinical oncology. From the fundamentals of pathophysiology to the latest developments in experimental and novel therapies, Current Clinical Oncology is an indispensable resource for today’s practicing oncologist.
Toate formatele și edițiile | Preț | Express |
---|---|---|
Paperback (1) | 1632.41 lei 6-8 săpt. | |
Humana Press Inc. – 2 apr 2015 | 1632.41 lei 6-8 săpt. | |
Hardback (1) | 1342.48 lei 38-44 zile | |
Humana Press Inc. – 8 mar 2013 | 1342.48 lei 38-44 zile |
Din seria Current Clinical Oncology
- 5% Preț: 1696.75 lei
- 5% Preț: 724.70 lei
- 5% Preț: 1160.99 lei
- 5% Preț: 780.45 lei
- 5% Preț: 1802.48 lei
- 5% Preț: 1430.90 lei
- 5% Preț: 1430.72 lei
- 5% Preț: 1345.79 lei
- 5% Preț: 1614.67 lei
- 5% Preț: 1431.09 lei
- 5% Preț: 781.17 lei
- 5% Preț: 1112.54 lei
- 5% Preț: 1976.58 lei
- 5% Preț: 1106.86 lei
- 5% Preț: 1106.33 lei
- 5% Preț: 788.32 lei
- 5% Preț: 1617.62 lei
- 5% Preț: 1597.14 lei
- 5% Preț: 778.80 lei
- 5% Preț: 1824.77 lei
- 5% Preț: 1119.47 lei
- 5% Preț: 1114.71 lei
- 5% Preț: 743.69 lei
- 5% Preț: 1097.91 lei
- 5% Preț: 374.20 lei
- 5% Preț: 1593.27 lei
- 5% Preț: 783.04 lei
- 5% Preț: 1107.94 lei
- 5% Preț: 1101.21 lei
- 5% Preț: 775.33 lei
Preț: 1342.48 lei
Preț vechi: 1413.13 lei
-5% Nou
Puncte Express: 2014
Preț estimativ în valută:
256.91€ • 266.59$ • 214.73£
256.91€ • 266.59$ • 214.73£
Carte tipărită la comandă
Livrare economică 11-17 martie
Preluare comenzi: 021 569.72.76
Specificații
ISBN-13: 9781603279680
ISBN-10: 1603279687
Pagini: 950
Ilustrații: XXI, 538 p.
Dimensiuni: 210 x 279 x 38 mm
Greutate: 1.5 kg
Ediția:2013
Editura: Humana Press Inc.
Colecția Humana
Seria Current Clinical Oncology
Locul publicării:Totowa, NJ, United States
ISBN-10: 1603279687
Pagini: 950
Ilustrații: XXI, 538 p.
Dimensiuni: 210 x 279 x 38 mm
Greutate: 1.5 kg
Ediția:2013
Editura: Humana Press Inc.
Colecția Humana
Seria Current Clinical Oncology
Locul publicării:Totowa, NJ, United States
Public țintă
ResearchCuprins
1. Overview.- 2. Introduction to Cancer Surveillance Strategies.- 3. Using Decision Analysis to Model Cancer Surveillance.- 4. Cancer Survivorship: Monitoring the Long-Term and Late Effects of Treatment.- 5. Upper Aerodigestive Tract Carcinoma.- 6. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Europe.- 7. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Japan.- 8. Upper Aerodigestive Tract Carcinoma Surveillance Counterpoint: Canada.- 9. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma.- 10. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma Surveillance Counterpoint: Australia.- 11. Thyroid (Papillary, Follicular, Medullary, Hürthle Cell) Carcinoma Surveillance Counterpoint: Japan.- 12. Lung Carcinoma.- 13. Lung Carcinoma Surveillance Counterpoint: Australia.- 14. Lung Carcinoma Surveillance Counterpoint: Japan.- 15. Lung Carcinoma Surveillance Counterpoint: Canada.- 16. Esophagus Carcinoma.- 17. Esophagus Carcinoma Surveillance Counterpoint: Australia.- 18. Esophagus Carcinoma Surveillance Counterpoint: Japan.- 19. Stomach.- 20. Stomach Carcinoma Surveillance Counterpoint: USA.- 21. Stomach Carcinoma Surveillance Counterpoint: Japan.- 22. Pancreatic Adenocarcinoma.- 23. Pancreatic Adenocarcinoma Surveillance Counterpoint: USA.- 24. Pancreatic Adenocarcinoma Surveillance Counterpoint: Europe.- 25. Pancreatic Adenocarcinoma Surveillance Counterpoint: Japan.- 26. Pancreatic Adenocarcinoma Surveillance Counterpoint: Canada.- 27. Liver and Biliary Tract Carcinoma.- 28. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Europe.- 29. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Australia.- 30. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Japan.- 31. Liver and Biliary Tract Carcinoma Surveillance Counterpoint: Canada.- 32. Colon and Rectum Carcinoma.- 33. Colon and Rectum Carcinoma Surveillance Counterpoint: USA.- 34. Colon and RectumCarcinoma Surveillance Counterpoint: Australia.- 35. Colon and Rectum Carcinoma Surveillance Counterpoint: Japan.- 36. Colon and Rectum Carcinoma Surveillance Counterpoint: Canada.- 37. Anal Carcinoma.- 38. Anal Carcinoma Surveillance Counterpoint: USA.- 39. Anal Carcinoma Surveillance Counterpoint: Australia.- 40. Anal Carcinoma Surveillance Counterpoint: Japan.- 41. Anal Carcinoma Surveillance Counterpoint: Canada.- 42. Soft Tissue Sarcoma.- 43. Soft Tissue Sarcoma Surveillance Counterpoint: USA.- 44. Soft-Tissue Sarcoma Surveillance Counterpoint: Japan.- 45. Soft Tissue Sarcoma Surveillance Counterpoint: Canada.- 46. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma.- 47. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma Surveillance Counterpoint: Japan.- 48. Osteogenic Sarcoma and Dedifferentiated Chondrosarcoma Surveillance Counterpoint: Canada.- 49. Cutaneous Melanoma.- 50. Cutaneous Melanoma Surveillance Counterpoint: USA.- 51. Cutaneous Melanoma Surveillance Counterpoint: Australia.- 52. Cutaneous Melanoma Surveillance Counterpoint: Japan.- 53. Breast Carcinoma.- 54. Breast Carcinoma Surveillance Counterpoint: USA.- 55. Breast Carcinoma Surveillance Counterpoint: Europe.- 56. Breast Carcinoma Surveillance Counterpoint: Australia.- 57. Breast Carcinoma Surveillance Counterpoint: Japan.- 58. Endometrial Carcinoma.- 59. Endometrial Cancer Surveillance Counterpoint: USA.- 60. Endometrial Cancer Surveillance Counterpoint: USA.- 61. Carcinoma of the Endometrium Surveillance Counterpoint: Japan.- 62. Endometrial Carcinoma Surveillance Counterpoint: Canada.- 63. Cervical Carcinoma.- 64. Cervical Carcinoma Surveillance Counterpoint: USA.- 65. Cervical Carcinoma Surveillance Counterpoint: Japan.- 66. Cervical Carcinoma Surveillance Counterpoint: Canada.- 67. Vaginal and Vulvar Carcinoma.- 68. Vaginal and Vulvar Carcinoma Surveillance Counterpoint: Japan.- 69. Ovarian Carcinoma.- 70. Ovarian Carcinoma Surveillance Counterpoint:USA.- 71. Ovarian Cancer Surveillance Counterpoint: Europe.- 72. Ovarian Cancer Surveillance Counterpoint: Japan.- 73. Renal Carcinoma.- 74. Renal Carcinoma Surveillance Counterpoint: Europe.- 75. Renal Carcinoma Surveillance Counterpoint: Japan.- 76. Renal Carcinoma Surveillance Counterpoint: Canada.- 77. Urinary Bladder Carcinoma.- 78. Urinary Bladder Carcinoma Surveillance Counterpoint: Japan.- 79. Urinary Bladder Carcinoma Surveillance Counterpoint: Canada.- 80. Prostate Carcinoma.- 81. Prostate Carcinoma Surveillance Counterpoint: USA.- 82. Prostate Carcinoma Surveillance Counterpoint: USA.- 83. Prostate Carcinoma Surveillance Counterpoint: Europe.- 84. Prostate Carcinoma Surveillance Counterpoint: Japan.- 85. Prostate Carcinoma Surveillance Counterpoint: Canada.- 86. Testicle Carcinoma.- 87. Testicle Carcinoma Surveillance Counterpoint: USA.- 88. Testicle Carcinoma Surveillance Counterpoint: Australia.- 89. Testicle Carcinoma Surveillance Counterpoint: Japan.- 90. Lymphoma.- 91. Lymphoma Surveillance Counterpoint: USA.- 92. Lymphoma Surveillance Counterpoint: Japan.- 93. Lymphoma (Following Autologous Stem Cell Transplant).- 94. Lymphoma (Following Autologous Stem Cell Transplant) Surveillance Counterpoint: Japan.- 95. Leukemia.- 96. Leukemia Surveillance Counterpoint: USA.- 97. Leukemia Surveillance Counterpoint: Japan.- 98. Multiple Myeloma.- 99. Multiple Myeloma Surveillance Counterpoint: USA.- 100. Multiple Myeloma Surveillance Counterpoint: Australia.- 101. Multiple Myeloma Surveillance Counterpoint: Japan.- 102. Multiple Myeloma Surveillance Counterpoint: Canada.- 103. Glioma of the Central Nervous System.- 104. Glioma of the Central Nervous System Surveillance Counterpoint: Europe.- 105. Glioma of the Central Nervous System Surveillance Counterpoint: Australia.- 106. Glioma of the Central Nervous System Surveillance Counterpoint:Japan.
Recenzii
From the reviews:
“This book discusses surveillance strategies for patients completing curative-intent primary treatment for cancer. … Members of the oncology treatment team as well as primary care health professionals who provide post-treatment follow-up survivorship care will benefit from this informative, disease-specific resource. … This is an extremely valuable and useful compilation of cancer site-specific surveillance guidelines for follow-up of asymptomatic patients who have completed primary treatment with curative intent.” (Judith G. Abramson, Doody’s Book Reviews, September, 2013)
“Patient Surveillance After Cancer Treatment is a well-written, well-organized reference designed to speak to any practicing oncologist or primary care provider that follows cancer patients after treatment for curative intent. … This is a great text and reference to any clinically practicing oncologist, primary care provider, survivorship program, and training physician of any level. Patient Surveillance After Cancer Treatment will continue to prove itself useful and will be readily available in our library.” (Nima Nabavizadeh and David Elliott, Journal of Radiation Oncology, Vol. 2 (3), September, 2013)
“This book discusses surveillance strategies for patients completing curative-intent primary treatment for cancer. … Members of the oncology treatment team as well as primary care health professionals who provide post-treatment follow-up survivorship care will benefit from this informative, disease-specific resource. … This is an extremely valuable and useful compilation of cancer site-specific surveillance guidelines for follow-up of asymptomatic patients who have completed primary treatment with curative intent.” (Judith G. Abramson, Doody’s Book Reviews, September, 2013)
“Patient Surveillance After Cancer Treatment is a well-written, well-organized reference designed to speak to any practicing oncologist or primary care provider that follows cancer patients after treatment for curative intent. … This is a great text and reference to any clinically practicing oncologist, primary care provider, survivorship program, and training physician of any level. Patient Surveillance After Cancer Treatment will continue to prove itself useful and will be readily available in our library.” (Nima Nabavizadeh and David Elliott, Journal of Radiation Oncology, Vol. 2 (3), September, 2013)
Notă biografică
Dr. Frank E. Johnson, MD
Textul de pe ultima copertă
Patient Surveillance After Cancer Treatment covers the history of cancer patient surveillance after curative-intent treatment, the rationale, the methodologies used in the past and at present, the methodologies that will probably emerge in the future, the costs of surveillance, the definitions of various terms used in the field, and how those who are interested in the topic can get more information about it from the internet. The secondary focus of the book is to publicize the need for well-designed, adequately powered randomized clinical trials comparing two (or more) surveillance strategies for each type of cancer.
The audience includes all oncologists, cancer researchers, medical economists and policy makers in government and insurance companies, and finally, interested patients.
This book is part of the Current Clinical Oncology series, which provides cutting-edge knowledge of cancer diagnosis, management, and treatment. World renowned experts share their insights in all the major fields of clinical oncology. From the fundamentals of pathophysiology to the latest developments in experimental and novel therapies, Current Clinical Oncology is an indispensable resource for today’s practicing oncologist.
The audience includes all oncologists, cancer researchers, medical economists and policy makers in government and insurance companies, and finally, interested patients.
This book is part of the Current Clinical Oncology series, which provides cutting-edge knowledge of cancer diagnosis, management, and treatment. World renowned experts share their insights in all the major fields of clinical oncology. From the fundamentals of pathophysiology to the latest developments in experimental and novel therapies, Current Clinical Oncology is an indispensable resource for today’s practicing oncologist.
Caracteristici
History of cancer patient surveillance after curative-intent treatment Inform those on the subject of cancer Definitions of various terms used in the field